HSA — authorised 20 December 2019
- Marketing authorisation holder: DAIICHI SANKYO
- Status: likely_approved
HSA authorised Enhertu on 20 December 2019
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. HSA authorised it on 20 December 2019.
DAIICHI SANKYO holds the Singaporean marketing authorisation.